- Home
- LSBK vs AGEN Comparison
LSBK vs AGEN Comparison
Compare LSBK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | AGEN |
|---|---|---|
| Founded | 1891 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 126.2M |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LSBK | AGEN |
|---|---|---|
| Price | $15.43 | $2.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 4.5K | ★ 892.1K |
| Earning Date | 01-21-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | $28,018,000.00 | ★ $106,829,000.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | ★ 8.40 | N/A |
| 52 Week Low | $11.50 | $1.38 |
| 52 Week High | $16.95 | $7.34 |
Technical Indicators
Market Signals| Indicator | LSBK | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 35.33 |
| Support Level | $15.26 | $2.71 |
| Resistance Level | $15.74 | $2.96 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 50.00 | 8.33 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).